Alkem Laboratories Ltd.

Financial

	Alkem Laboratories	Mankind Pharma	Cipla
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	176.0 .	55.0 .	277.0 .
Number of ANDA's Approved By USFDA	145.0 .	32.0 .	196.0 .
Number of ANDA's Filed in Europe	18.0	n/a	n/a
Number of ANDA's Approved in Europe	12.0	n/a	n/a
Number of ANDA's Filed in Australia	42.0	n/a	n/a
Number of ANDA's Approved by Australia	32.0	n/a	n/a
Domestic Sales Growth - YoY	10.8 %	n/a	9.1 %
R&D as a % of Total Sales	6.0 %	2.15 %	7.2 %
Financials
5 yr Average ROE	16.74 %	23.48 %	11.43 %
5yr average Equity Multiplier	1.42	1.4	1.39
5yr Average Asset Turnover Ratio	0.9	1.02	0.76
5yr Avg Net Profit Margin	13.14 %	16.52 %	10.96 %
Price to Book	5.71	9.11	4.5
P/E	32.76	44.58	29.16
5yr Avg Cash Conversion Cycle	0.57 Days	-45.92 Days	-3.69 Days
Inventory Days	55.43 Days	60.23 Days	59.85 Days
Days Receivable	40.86 Days	19.33 Days	44.13 Days
Days Payable	116.85 Days	132.42 Days	114.64 Days
5yr Average Interest Coverage Ratio	24.09	47.23	23.71
5yr Avg ROCE	22.27 %	31.06 %	15.24 %
5yr Avg Operating Profit Margin	19.27 %	25.32 %	22.51 %
5 yr average Debt to Equity	0.22	0.07	0.13
5yr CAGR Net Profit	5.29 %	17.25 %	12.9 %
5yr Average Return on Assets	11.73 %	16.73 %	8.36 %
Shareholdings
Promoter Holding	56.74 %	74.88 %	33.47 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-3.42 %	-1.62 %	-3.26 %
Change in Mutual Fund Holding (3 Yrs)	5.03 %	6.74 %	2.19 %

Business

	Alkem Laboratories	Mankind Pharma	Cipla
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 100.0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 New ventures 0 Pharmaceuticals 0	Product Wise Break-Up Gastrointestinal 10.0 New ventures 0 Pain/Analgesics 4.0 Gynaecology 8.0 Pharmaceuticals 0 Anti-Diabetic 8.0 Dermatology 5.0 Cardiovascular 15.0 Urology 6.0 Respiratory 9.0 Pharmaceutical 0 VMN 9.0 Neuro/CNS 3.0 Anti-infectives 15.0 Others 8.0	Product Wise Break-Up Gastro - Intestinal 0 New ventures 3.43 Pain/Analgesics 0 Gynaecology 0 Pharmaceutical 96.57 Anti-Diabetic 0 Dermatology 0 Cardiovascular 0 Urology 0 Respiratory 0 Pharmaceutical 0 VMN 0 Neuro/CNS 0 Anti-infectives 0
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Anti-Infective 37.6 Gastro Intestinal 18.6 Pain Management 10.9 Vitamins / Minerals / Nutrients 10.3 Anti - Diabetes 4.0 Gynecology 4.0 Central Nervous System (CNS) 3.8 Respiratory 3.3 Derma 2.8 Cardiac Science 2.3 Urology 0 Antivirals 0 Neuro /CNS 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Opthal/Otologicals 0 Oncology 0 Anti Diabetic 0 Others 2.4	-	Therapeutic Area Wise Break-Up - Domestic Central Nervous System (CNS) 0 Vitamins / Minerals / Nutrients 0 Urology 4.8 Respiratory Systems 38.9 Antineoplast 0 Oncology 0 Anti-Infective 0 Pain Management 0 Vitamins 0 Anti - Diabetes 0 Ophthalmology 3.1 Gynecology 0 Cardiac Science 0 Central Nervous System (CNS) 2.3 Gastro Intestinal 5.8 Antivirals 3.1 Gynaec. 0 Anti - Diabetes 3.8 Derma 2.7 Others 35.5
Location Wise Break-Up	Location Wise Break-Up India 67.18 USA 30.98 Nepal 0 Sri Lanka 0 Bangladesh 0 SAGA 0 Europe 0 Global API 0 Rest of the World 0 Emerging Markets 0 North America 0 Others 1.84	Location Wise Break-Up SAGA 0 Emerging Markets 0 USA 0 Europe 0 India 89.0 Bangladesh 0 Nepal 0 Global API 0 North America 0 Sri Lanka 0 Rest of the World 0 Others 11.0	Location Wise Break-Up SAGA 12.0 Emerging Markets 0 USA 0 Europe 0 India 44.0 Bangladesh 0 Nepal 0 Global API 2.0 North America 29.0 Sri Lanka 0 Rest of the World 11.0 Others 2.0
Asset Break-Up	Asset Break-Up India 85.09 USA 13.19 South Africa 0 Others 1.72	-	Asset Break-Up India 47.79 South Africa 16.85 USA 30.05 Others 5.31

Alkem Laboratories Ltd.

SIGN UP FOR FREE